Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis? Data from the German National Psoriasis Registry PsoBest
Early and effective treatment of PsA is crucial to prevent persistent damage of the joints. Although most patients received recommended systemic treatment for PSO+PsA, there is a small number of patients with prescriptions addressing mainly the inflammation of the skin and not explicitly PsA. To choose recommended medication for both entities we need to regard the entire systemic inflammation and interdisciplinary co-working should be implemented.
Authors
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Christine Blome (ORCID: https://orcid.org/0000-0002-1163-1639)
- Ralph von Kiedrowski (ORCID: https://orcid.org/0009-0007-5004-0982)
- Christina Sorbe (ORCID: https://orcid.org/0000-0001-5809-3463)
- Ansgar Weyergraf (ORCID: https://orcid.org/0000-0001-5221-2492)
- Brigitte Stephan (ORCID: https://orcid.org/0000-0001-6127-3692)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Secilay Kargin
Institutions
- Universität Hamburg (DE)
- Wallace Community College Selma (US)
- University Medical Center Hamburg-Eppendorf (DE)
- B. Braun (Netherlands) (NL)
- University of Lübeck (DE)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ptt.s524083
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Biogen
- Celgene
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Mylan
- Celltrion
- Deutsche Forschungsgemeinschaft
- Galderma
- Medac
- LEO Pharma
- Samsung
- Universitätsklinikum Hamburg-Eppendorf
- Cilag